ATE378069T1 - Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine - Google Patents

Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine

Info

Publication number
ATE378069T1
ATE378069T1 AT02769112T AT02769112T ATE378069T1 AT E378069 T1 ATE378069 T1 AT E378069T1 AT 02769112 T AT02769112 T AT 02769112T AT 02769112 T AT02769112 T AT 02769112T AT E378069 T1 ATE378069 T1 AT E378069T1
Authority
AT
Austria
Prior art keywords
cell death
antibody
ntp
antibodies against
neural thread
Prior art date
Application number
AT02769112T
Other languages
English (en)
Inventor
Paul Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Application granted granted Critical
Publication of ATE378069T1 publication Critical patent/ATE378069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02769112T 2001-05-04 2002-05-06 Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine ATE378069T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28846301P 2001-05-04 2001-05-04

Publications (1)

Publication Number Publication Date
ATE378069T1 true ATE378069T1 (de) 2007-11-15

Family

ID=23107207

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769112T ATE378069T1 (de) 2001-05-04 2002-05-06 Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine

Country Status (10)

Country Link
US (1) US20030003445A1 (de)
EP (1) EP1387698B1 (de)
JP (1) JP2004528367A (de)
KR (1) KR20040029968A (de)
CN (1) CN1635906A (de)
AT (1) ATE378069T1 (de)
AU (1) AU2002308327B2 (de)
CA (1) CA2446480A1 (de)
DE (1) DE60223524D1 (de)
WO (1) WO2002089841A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880816A (en) * 1982-05-18 1989-11-14 University Of Florida Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium salt-type redox carriers
US5187158A (en) * 1982-05-18 1993-02-16 University Of Florida Brain-specific drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
ES2094733T3 (es) * 1988-12-21 1997-02-01 Gen Hospital Corp Deteccion de enfermedades o disfunciones neurologicas.
NZ337445A (en) * 1997-02-26 2000-12-22 Gen Hospital Corp Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
AU8269898A (en) * 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
AU2002304314B2 (en) * 2001-03-08 2007-09-06 Nyomox Pharmaceutical Corporation Using neural thread proteins to treat tumors and other hyperproliferative disorders
US6770797B2 (en) * 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid

Also Published As

Publication number Publication date
CN1635906A (zh) 2005-07-06
EP1387698B1 (de) 2007-11-14
US20030003445A1 (en) 2003-01-02
CA2446480A1 (en) 2002-11-14
WO2002089841A3 (en) 2003-04-24
KR20040029968A (ko) 2004-04-08
JP2004528367A (ja) 2004-09-16
AU2002308327B2 (en) 2006-11-30
EP1387698A2 (de) 2004-02-11
DE60223524D1 (de) 2007-12-27
WO2002089841A2 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
ATE401079T1 (de) Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
ATE399007T1 (de) Raf kinase hemmer
DE69629578D1 (de) Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut
ATE431811T1 (de) Verwendung mehrwertiger metallkarbonate zur vorbeugung von kalksteinablagerung
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE322290T1 (de) Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia
BR9903571A (pt) Método para inibição de glicogênio fosforilase humano
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
IL149890A0 (en) Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated
BR9910511A (pt) Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
ATE315939T1 (de) Verfahren zur prophylaxe oder kontrolle des katarakts
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
ATE328605T1 (de) Verwendung von insulin zur behandlung von knorpelkrankheiten
BRPI0417674A (pt) método para tratar a inflamação aguda em animais, com inibidores de quinase map p38
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
ATE381342T1 (de) Prävention des zelltodes durch verwendung von segmenten der neurofilamentproteinen
DE60223524D1 (de) Verfahren zur vorbeugung von zelltod unter verwendung von antikörpern gegen neural thread proteine
ATE338031T1 (de) Verfahren zur hemmung von korrosion unter verwendung von isomeren des chlormethylbenzotriazols

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties